Orthofix Q1 pro forma revenue $196.4M +2.7% constant currency; reaffirms FY guidance

Orthofix Medical Inc.

2026-Q1 EPS reported -$0.52 revenue$196,708,000

GAAP net loss $(20.9)M vs $(53.1)M prior year; adjusted EBITDA $9.7M (4.9% of pro forma sales) vs $11.4M (6.0%) prior year.
Global Spine Fixation +6%, Therapeutic Solutions +5%, Limb Reconstruction +10% reported (+3% constant currency).
Reaffirms FY2026 net sales $850M-$860M, adjusted EBITDA $95M-$98M, positive free cash flow.
Cash $120.9M at March 31, 2026; plans to repay $424M 0.875% exchangeable notes due June 2026.
Distributor transitions largely behind; expects improved commercial execution and product launches later in 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Orthofix Medical Inc. reported the first quarter ended March 31, 2026 results: revenue $196.7 million, net income $(20.9) million, EPS $(0.52) per share. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $196.7 million
Net income: $(20.9) million
EPS: $(0.52) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

measures contained within this release exclude the impact of the Company’s decision to discontinue its M6TM product lines. Highlights • First quarter 2026 reported net sales of $196.7 million, including sales from M6 artificial cervical and lumbar discs. Non-GAAP pro forma net sales of $196.4 million, excluding sales from M6 discs, increased 3% year over year on a

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Orthofix Medical Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-204999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.